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McElhaugh: Hematuria Status Post Renal Biopsy

Case Presentations

Hematuria Status-post Renal Biopsy
William McElhaugh, MD, Resident, Department of Internal Medicine 1998-2001

This is a case of a 66 year old Caucasian woman admitted
to the hospital following a ureteroscopic biopsy of the left
renal pelvis. The biopsy was performed for asymptomatic
hematuria, with a retrograde intravenous pyelogram
revealing a mass in the left renal pelvis. The patient developed lightheadedness and left flank pain 12-24 hours following the procedure and was found to have a 3 gram
drop in hemoglobin compared to blood work performed
during the previous week.
One week prior to the biopsy, the following lab studies
were done: hemoglobin 10.4 gm/dL, platelets
230,000/mL3, creatinine 1.0 mg/dL, prothrombin time
(PTT) 41 seconds (25-35), and protime (PT) 12 seconds
(11-13). On admission, a CT scan was performed which
showed a large left subcapsular renal hematoma with blood
in the peritoneal space. Repeat labs at the time of admis3
sion were: hemoglobin 7.4 mg/dL, platelets 311,000/mL ,
creatinine 3.4 mg/dL, PTT was 46 seconds, PT 13 seconds.
She was transferred to the intensive care unit and stabilized
with intraveinous fluids and blood products.
Her past medical history included hypertension, hypothyroidism, post-operative deep vein thrombosis (15 yrs ago),
and recent hematuria. Her past surgical history included
hip replacement, which was not complicated by bleeding
diathesis. Her social history was not significant for any
alcohol or tobacco use. Medications included levothyroxine and amlodipine, which she had been taking for some
time. She denied the use of over the counter products,
such as aspirin or ibuprofen. There was no family history
of bleeding disorders.
Physical exam at the time of admission to the intensive
care unit revealed a temperature of 99 degrees Fahrenheit,
heart rate of 92, blood pressure of 104/80 mm/Hg (following fluids), and SaO2 of 93% on room air. Pertinent
positive findings included bibasilar crackles, and left flank
tenderness without any rebound or guarding. Pertinent
negatives included no skin lesions or ecchymoses.
On the day of admission to the intensive care unit, the
patient underwent an arteriogram, which localized the
site of bleeding to the biopsy site. During the arteriogram, multiple coils were inserted in the vicinity of

the bleed, but hemostasis was unable to be achieved.
Within the first 24 hours, 16 units of fresh frozen
plasma were given without achieving hemostasis, and
2-4 units of packed red blood cells were needed to
maintain a stable hemoglobin. Two days into admission, she underwent a procedure to embolize the vascular supply to the region where the bleeding was
originating from. Transfusion requirements and the
degree of hematuria were decreased, however, in the
groin, oozing was still present at the site of arteriogram
catheter insertion.
Discussion
The patient underwent a routine procedure that can be
complicated by hematuria, however, hematuria to this
degree is extremely rare. During the ureteroscopic procedure, no discrete mass could be identified. Biopsies were
taken in the region that the abnormality was noted on
intravenous pyelogram. Transitional cell carcinoma comprises 90% of malignancies in this region and does not
have a propensity for bleeding, however, renal cell and
metastatic melenoma can occur and both are very vascular tumors. The diagnostic test of choice for renal cell
carcinoma is CT with contrast. This was performed during the initial work up one to two months prior to the
biopsy with no masses noted. In the majority of cases, it
would be expected to find a skin lesion or a history of a
lesion in the past if metastatic melenoma was suspected
in the differential. No lesions were noted.
Platelet disorders may also cause a persistent bleed. In
this case, both pre-biopsy and post-biopsy platelet count
were within normal limits. The possibility of a qualitative platelet dysfunction remained. The most common
cause is drugs a list of which includes non-steroidal antiinflammatory drugs, penicillins, cephalosporins, and
heparin. Alcohol also has a strong effect on platelet function. The patient denied use of any of these. Uremia also
decreases platelet function, and she presented with an
elevated creatinine on admission. Her acute renal failure,
however, was likely the result of a combination of direct
nephron damage from bleeding in addition to hemodynamic instability. The patient’s renal function gradually
improved throughout hospitalization.
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Coagulopathy, like platelet dysfunction, can also lead to
this degree of bleeding. On pre-operative labs it was noted
that her PTT was slightly elevated. PTT is used to monitor heparin therapy and screen for abnormalities in the
factors of the intrinsic pathway. It is a measure of all the
blood factors except Factor VII. The PT is used to evaluate the extrinsic pathway and becomes prolonged when
factors drop below 50% of their normal range. Emphasis
must be placed on the fact that an abnormal PTT needs
immediate attention. One second over normal represents
a concentration of one of the intrinsic factors less than
25%. The hematology consult group evaluated the patient
and suspected that the bleeding diathesis was related to
the abnormal PTT. Appropriate measures were taken for
both the treatment and diagnosis.
When evaluating a patient that presents with a prolonged PTT, it is important to first review the medication list for medications such as heparin. The next step is
to perform a mixing study. In a mixing study, the
patient’s blood is mixed with an equal amount of blood
from a donor with normal partial PTT. After mixing, the
PTT is rechecked, and if it has corrected to within the
normal range, then an intrinsic factor deficiency is present. If the PTT does not normalize, then a factor
inhibitor or lupus anticoagulant are the most likely etiology. The mixing study in this patient did not correct
(PTT=41) and it was strongly suspected that the patient
possessed an inhibitor to an intrinsic factor.

or more episodes of major bleeding. As in this case, the
hallmark of a Factor VIII inhibitor is the prolongation of
the PTT with a normal PT. This pattern also occurs with
factor deficiencies, but as previously mentioned, the mixing study is used to differentiate the two conditions.
When normal plasma is mixed with plasma containing
an inhibitor, the PTT remains prolonged. A repeated PTT
one to two hours after the plasma is mixed is essential
because weak inhibitors require time to inactivate the factor. The mixing study suggested an inhibitor, and the
next step was to perform the Bethesda assay. The Bethesda
assay establishes the diagnosis and gives quantitative
information. One Bethesda Unit (BU) is defined as the
reciprocal of the patient plasma dilution that creates a
50% residual Factor VIII activity in the test system. This
assay tends to underestimate the effect of the inhibitor.

From a diagnostic standpoint, the work up centered on
determination of which factor was inhibited, and to what
degree. Factor VIII inhibitors are by far the most common acquired inhibitors, with an incidence of about one
per million annually. Patients usually present after fifty
years of age. The autoantibodies are IgG molecules that
are directed against the A2 or C2 domains of the Factor
VIII molecule. The patient’s Factor VIII level was 0.02
(0.46-1.5) and Factor VIII antibody level was 21.7
(<0.6). Factor IX and XI deficiencies may also present
like this. These factor levels were normal in this case.

Management of these patients entails both control of
acute bleeding and elimination of inhibitor to Factor
VIII. Therapy to control bleeding is based on the titer of
the inhibitor. For example, with low-titer inhibitors (<5
BU) use of DDAVP or human Factor VIII may control
bleeding. High-titer inhibitors (>5 BU) require porcine
Factor VIII or recombinant Factor VIIa. The patient had
an inhibitor level of 21.7 BU and recombinant Factor
VIIa was started. Factor VIIa is given in a dose of 90
ug/kg IV every two to three hours. The factor binds to
tissue factor at sites of injury activating Factor X, which
results in local thrombin formation. The duration of
treatment is variable and based on clinical improvement.
With our patient, signs of bleeding abated almost instantaneously when Factor VIIa infusion was begun. She
required approximately 3 days of treatment. The other
course of treatment, which was not used in this case, is
porcine Factor VIII. Most inhibitors cross-react minimally with porcine factor as compared to exogenous
human Factor VIII. When a Factor VIII inhibitor is suspected, an inhibitor level to porcine Factor VIII is sent
with other labs which measure the factor level and antibody titer. This patient had a porcine Factor VIII antibody level less than 0.6 (<0.6).

Clinical manifestations of a Factor VIII inhibitor are primarily bleeding into skin or muscle, but bleeding can
occur at any site. More than 80% of individuals have one

The recommendations regarding long term management
are anecdotal and often unsuccessful. The factors that predispose to formation of these inhibitors are unknown, and
(Continued on next page)
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in one-third of the cases the inhibitors will spontaneously
disappear. Typically, prednisone is the initial agent used to
eradicate the inhibitor. Responders generally have higher
factor levels and lower inhibitor levels at presentation. If
prednisone is not effective, then a trial of chemotherapy is
warranted. Commonly used agents include cyclophosphamide, azathioprine, and cyclosporine.
As previously mentioned, the etiology of inhibitor formation is unclear, but there are certain conditions with which
it is associated. Hemophilia is by far the most common
predisposing condition. Systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA) and malignancies are
also frequently associated with the presence of inhibitors.
No clinical or laboratory signs were noted for SLE or RA
in the above patient. She presented with acute renal failure and a twenty-four hour creatinine and protein were
sent. Results revealed proteinuria with 1.8 grams of
lambda light chain. Serum protein electrophoresis (SPEP)
also revealed a lambda light chain spike. Bone marrow
biopsy revealed 20% plasma cells and serum gamma
globulins were decreased. With this information, criteria
were met for the diagnosis of multiple myeloma. An association between multiple myeloma and Factor VIII
inhibitor has been noted, but is extremely rare.
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This patient had a Factor VIII inhibitor, likely caused by
the multiple myeloma. This case emphasizes the need to
approach the bleeding patient with a broad differential.
One of the most common initial presentations of patients
with factor inhibitors is persistent bleeding following a
minor surgical procedure. This patient also had an elevated PTT on pre-operative labs, which indicated a factor level less than 25% of one of the intrinsic factors.
Whenever an unexplained elevation of the PTT is noted,
a mixing study must be performed. The mixing study
will differentiate between a factor deficiency versus factor inhibitor. As a general internist, emphasis must be
placed on early suspicion of these types of cases followed
by initiation of a proper work up.
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